drugset / Trial / NCT01234519
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Phase 1/2
Terminated
12 enrolled
AEterna Zentaris
Miami VA Healthcare System · collabUniversity of Miami · collabUniversity of Miami Sylvester Comprehensive Cancer Center · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
Timeline
- Start
- 2010-11
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zoptarelin doxorubicin | Other / unclassified | 128 mg/m2 | Intravenous |
| Subject | zoptarelin doxorubicin | Other / unclassified | 160 mg/m2 | Intravenous |
| Subject | zoptarelin doxorubicin | Other / unclassified | 210 mg/m2 | Intravenous |
| Subject | zoptarelin doxorubicin | Other / unclassified | 267 mg/m2 | Intravenous |